From the Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
Alfonso Quintás-Cardama, William Wierda, Susan O'Brien
The use of rituximab-based chemoimmunotherapy regimens has remarkably improved the response rates, long-term outcomes, and quality of life of patients with B-cell malignancies. However, a substantial number of patients exhibit either primary or acquired resistance to rituximab, which suggests that novel immunotherapeutics with distinct mechanisms of action are necessary. A series of monoclonal antibodies with specificity against different surface antigens expressed on malignant B cells (eg, CD22, CD23, CD40, CD70) and novel immunotherapeutics (eg, bispecific monoclonal antibodies, small-modular immunopharmaceuticals, T-cell engagers) are currently in clinical or final preclinical stages of development. Although these agents offer reason for optimism, considerable challenges lie ahead in establishing their real clinical value, as well as in integrating them into current therapeutic algorithms for patients with B-cell malignancies. This review describes some of the most promising investigational immunotherapeutics for the treatment of B-cell malignancies.
Journal of Clinical Oncology
First Author: Bruce D. Cheson
Publish Date: May 10, 2010
Journal of Clinical Oncology
First Author: David G. Maloney
Publish Date: Sep 10, 2005
Journal of Clinical Oncology
First Author: Joshua Brody
Publish Date: Apr 11, 2011
Journal of Clinical Oncology
First Author: Daruka Mahadevan
Publish Date: Apr 11, 2011